Ru(III) complexes derived from N-methyl derivatives of glycine and 1,3-propylenediamine-N,N'-diacetato ligands and their activities against HeLa, K562 cell lines and human PBMC

Ruthenium(III) complexes formulated as K2[Ru(sar)Cl4]H2O and K[Ru(dmgly)2Cl2]3H2O containing bidentate chelates N-methylglycine (sarcosine, sar) or N,N-dimethylglycine (dmgly) as well as K[Ru(pdda)Cl2]2.5H2O complex with tetradentate 1,3-propylenediamine-N,N'-diacetato were synthesized. The complexes were obtained by direct reaction of ruthenium(III) chloride with the corresponding bidentate or tetradentate ligand followed by addition of a base (KOH). These new complexes were characterized by elemental analysis, IR and electronic absorption spectroscopy. To assess selectivity in the antitumor action of these complexes, their antiproliferative activities against human adenocarcinoma HeLa cells, human myelogenous leukemia K562 cells, human breast carcinoma MDA-MB-361 and MDA-MB-453 cells and normal immunocompetent PBM cells were determined.